The Roslin Institute in new industry collaboration
The Roslin Institute of the University of Edinburgh and NewVectys join forces to generate breakthrough innovations for human and animal health.
The Roslin Institute of the University of Edinburgh and NewVectys are pleased to announce that they have signed a general collaboration agreement with the objective of generating breakthrough innovations to address major challenges in human and animal health. Both parties will join their forces and complementary skills in the fields of vectorology, genetic engineering and animal biotechnology.
The Roslin Institute and NewVectys already cooperate on designing and developing new technologies for biomedical research, providing advanced solutions to accelerate development of new and effective disease therapies. The general collaboration agreement will reinforce the links between The Roslin Institute and NewVectys, and will allow new projects addressing human and animal health issues, such as infectious diseases and regenerative medicine.
The Roslin Institute at the University of Edinburgh receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC). The Institute undertakes top-class basic and translational science to tackle some of the most pressing issues in animal health and welfare, their implications for human health and for the role of animals in the food chain.
The Roslin Institute provides holistic solutions to global challenges in human and veterinary medicine and the livestock industry.
NewVectys is a French biotech company developing leading-edge genetic engineering technologies. Created almost two years ago, NewVectys emerged from the National Center for Scientific Research (CNRS), a French leading research organization, and Pierre & Marie Curie University (UPMC), which houses its R&D laboratory at the Hospital de la Piticute; Salpetriere in Paris. The company offers advanced customized tools for biomedical research notably bio-safe vectors and large animal models.
NewVectys also develops advanced therapies, leveraging its unique network of research partners, two decades of research experience and its genetic engineering proprietary technologies.